Login to Your Account



CHECKMATE stymied, BMS future Merck-y pending complete data

By Randy Osborne
Staff Writer

Friday, August 5, 2016

A "higher cut-point of PD-L1 expression" is probably necessary for a PD-1 monotherapy to work relative to chemotherapy in first-line non-small-cell lung cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription